STOCKS TELEGRAPH

Tag: AC Immune SA

  • AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data

    AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data

    Following the release of positive preliminary findings from its Phase 2 VacSYn clinical study, shares of AC Immune SA (NASDAQ: ACIU) saw a notable increase, jumping 13.42% on the charts. The anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056, which targets early-stage Parkinson’s disease (PD), is being evaluated in this experiment. ACIU stock ended Thursday’s trading session at $3.55 after the news.

    AC Immune Shares Promising Interim Data

    The interim results from the VacSYn trial provided positive data on the safety and immunogenicity of ACI-7104.056. These findings, which were gathered after just three months of treatment, demonstrate the promising immunogenicity levels and continued favorable safety profile.

    These findings establish ACI-7104.056 as a top choice for patients with early-stage Parkinson’s disease and confirm its potential as a best-in-class treatment candidate. In the first half of 2025, AC Immune intends to provide more information, which might include a decision to move forward with the trial’s second phase.

    VacSYn Study Design and Results

    VacSYn is an adaptive, placebo-controlled, biomarker-driven Phase 2 study targeting early Parkinson’s disease. The trial includes two phases, with Part 1 having already completed an analysis of over 30 patients, who were randomized to receive either ACI-7104.056 or a placebo.

    Notably, no significant safety concerns were identified, aside from mild side effects like injection site reactions (49%) and headaches (18%). The interim data indicated that ACI-7104.056 was effective in inducing a robust antibody response, with anti-a-syn antibodies reaching levels 16 times higher than the placebo after three immunizations.

    Future Plans and Expansion of the Study

    Looking ahead, AC Immune may expand Part 2 of the VacSYn trial, potentially involving up to 150 patients. This phase will explore additional outcomes, including the progression of motor and non-motor symptoms, as well as the use of digital, imaging, and fluid biomarkers. These efforts aim to establish early proof-of-concept and identify key biomarkers, supporting a swift transition into a pivotal study.

  • Strategic Boost: AC Immune’s (ACIU) Share Price Surges Pre-Market

    Strategic Boost: AC Immune’s (ACIU) Share Price Surges Pre-Market

    In response to recent strategic maneuvers, the shares of AC Immune SA (NASDAQ: ACIU) have experienced a notable surge in the pre-market session. At present, ACIU stock reflects an impressive uptick of 53.25% on the US charts, trading at $3.54.

    Revolutionary Collaboration Announced

    Today, AC Immune (ACIU) and Takeda established an exclusive global option and license arrangement. The businesses got into the arrangement with an emphasis on the AC Immune-developed active immunotherapies that target dangerous types of amyloid beta (Abeta). That also include its ACI-24.060, which is intended to treat Alzheimer’s disease.

    ACI-24.060 represents an anti-Abeta active immunotherapy candidate meticulously engineered to instigate a robust antibody response against the toxic forms of Abeta, recognized as catalysts for plaque formation and the progression of Alzheimer’s disease. Its mechanism, aimed at inducing plaque clearance and effectively impeding plaque formation in the brain, harbors the potential to retard or mitigate the advancement of Alzheimer’s disease.

    Pioneering Active Immunotherapy

    As pioneers in the realm of active immunotherapy, AC Immune is pioneering an innovative approach poised to revolutionize the treatment landscape for Alzheimer’s disease, addressing the multifaceted burden confronting patients and the wider community. The optimal realization of ACI-24.060’s impact is envisaged through collaboration with Takeda, facilitating an expedited progression into Phase 3 trials.

    AC Immune will oversee the completion of the ABATE trial. Subsequent to the exercise of the option, Takeda will spearhead and finance all ensuing clinical development endeavors, while assuming accountability for global regulatory undertakings and worldwide commercialization.

    Financial Implications

    Per the terms delineated in the agreement, AC Immune is slated to receive an upfront payment of $100 million, in addition to potential option exercise fees and a spectrum of development, commercial, and sales-based milestones, culminating in a cumulative sum of approximately $2.1 billion if all benchmarks are successfully met throughout the pact’s duration. Upon commercialization, AC Immune stands to garner tiered double-digit royalties on worldwide net sales.